Difficult-to-treat rheumatoid arthritis treated with Abatacept combined with Baricitinib: A case report

Figure 1 Doppler flow imaging and ultrasonographic pictures. A: Doppler flow imaging shows a few punctate blood flow signals in articular cavity (arrow); B: Ultrasonographic pictures showed that the synovial membrane of the joint was thickened, about 0.66 cm at the thickest point (bidirectional arrow); C: Doppler flow imaging shows abundant blood flow signal in articular cavity. D: Ultrasonographic pictures showed that the synovial membrane of the joint was thickened, about 1.07 cm at the thickest part (bidirectional arrow).

Figure 2 Clinical course of the patient (this statistic does not include tofacitinib because it was only utilized for two weeks). A: Doppler flow imaging showed abundant blood flow signal in the articular cavity in 2021-7-1 (arrow); B: Doppler flow imaging showed abundant blood flow signal in the articular cavity in 2021-10-1 (arrow); C: Doppler flow imaging showed a few punctate blood flow signal in the articular cavity in 2022-1-1 (arrow); HCQ: Hydroxychloroquine, 400 mg/day; IGU: Iguratimod, 50 mg/day; MTX: Methotrexate, 12.5 mg /week; TCZ: Tocilizumab, 400 mg/4 weeks; ETN: Etanercept, 50 mg/week; ADA: Adalimumab, 40 mg/2week; ABT: Abatacept, 250 mg/week; BAT: Bbaricitinib, 2 mg/day; ESR: Erythrocyte sedimentation rate; CRP: C-reactive protein; DAS28-ESR: Disease Activity Score for 28 joints with erythrocyte sedimentation rate.